Accelerating Implementation of Long-Acting Injectables
RWHAP Technical Assistance Provider updated on 06/11/2024
RWHAP Technical Assistance Provider updated on 06/11/2024
Blog updated 03/28/2024
RWHAP Technical Assistance Provider updated on 03/04/2024
Resource updated 08/17/2023
Resource updated 08/17/2023
Resource updated 09/14/2023
Resource from the RWHAP Best Practices Compilation updated on 11/01/2023
Resource from the RWHAP Best Practices Compilation updated on 01/07/2024
Resource from the RWHAP Best Practices Compilation updated on 04/15/2024
Resource from the RWHAP Best Practices Compilation updated on 11/01/2023
Resource updated 01/05/2024
Resource (Conference Presentation) updated 09/14/2023
Resource updated 08/17/2023
From the HRSA HIV/AIDS Bureau Listserv, 12/16/22
Resource (Conference Presentation) updated 09/14/2023
Resource (Conference Presentation) updated 09/14/2023
Resource (Conference Presentation) updated 09/14/2023
Resource (Conference Presentation) updated 09/14/2023
In a single-center restrospective cohort study, patients with extensive treatment experience and history of virologic failure and multi-drug resistance underwent simplification of ARV salvage regimens with a median pill burden reduction of six pills per day. This strategy led to high rates of virologic suppression.
Resource (Conference Presentation) updated 09/14/2023
The first long-acting injectable antiretroviral therapy (LAI ART) formulation was FDA-approved January 2021. Drawing on the Consolidated Framework on Implementation Research, this mixed methods study assessed knowledge, attitudes, practices, and perceived barriers and facilitators related to implementation of LAI ART in NYC among HIV clinic staff and people with HIV.
Resource (Conference Presentation) updated 09/14/2023